[Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors].
Cerivastatine was administered as a reversible HMG-CoA reductase inhibitor (statine) to treat hypercholesterolemia until its withdrawal from the market following 52 reports of death due to drug-related rhabdomyolysis and acute renal failure. In most cases, cerivastatine was applied in combination with drugs which influenced the liver metabolism of cerivastatine via cytochromeoxidase P 450 isoenzymes. We report a well-documented case of acute rhabdomyolysis following cerivastatine monotherapy. The diagnosis was confirmed additionally by muscle biopsy.Finally,we give an overview of the current knowledge concerning therapy with HMG-CoA reductase inhibitors,1 year after the withdrawal of cerivastatine from the market.
Sparing
R
R
Neurologische Klinik, Universitätsklinikum der RWTH Aachen.
Sellhaus
B
B
Noth
J
J
Block
F
F
D000208:Acute Disease; D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000502:physiology; D001706:Biopsy; D003067:Coenzymes; D015897:Comorbidity; D003402:Creatine Kinase / Q000097:blood; D065727:Cytochrome P-450 CYP2C8; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology; D003937:Diagnosis, Differential; D004347:Drug Interactions; D004576:Electromyography / Q000187:drug effects; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000201:enzymology; D008104:Liver Cirrhosis, Alcoholic / Q000175:diagnosis / Q000201:enzymology; D008111:Liver Function Tests; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000187:drug effects / Q000473:pathology; D009460:Neurologic Examination / Q000187:drug effects; D010182:Pancreatic Diseases / Q000175:diagnosis / Q000201:enzymology; D011725:Pyridines / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000175:diagnosis; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000201:enzymology; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000502:physiology
D000924:Anticholesteremic Agents; D003067:Coenzymes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; D014451:Ubiquinone; D003577:Cytochrome P-450 Enzyme System; C086276:cerivastatin; D001189:Aryl Hydrocarbon Hydroxylases; C450259:CYP2C8 protein, human; C104464:CYP3A protein, human; D065727:Cytochrome P-450 CYP2C8; D051544:Cytochrome P-450 CYP3A; D003402:Creatine Kinase; C024989:coenzyme Q10